Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Quote | Monopar Therapeutics Inc. (NASDAQ:MNPR)
Last: | $0.72 |
---|---|
Change Percent: | 2.29% |
Open: | $0.64 |
Close: | $0.72 |
High: | $0.73 |
Low: | $0.64 |
Volume: | 114,724 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Monopar Therapeutics Inc. (NASDAQ:MNPR)
WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging...
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Message Board Posts | Monopar Therapeutics Inc. (NASDAQ:MNPR)
Subject | By | Source | When |
---|---|---|---|
$1.40 Not nice. | willlbone | investorshub | 03/28/2023 3:52:30 PM |
$4+ nice | wesley_ | investorshub | 11/08/2022 9:35:40 PM |
Monopar Announces Completion of Phase 2b Enrollment and | subslover | investorshub | 10/05/2022 1:28:03 PM |
Well not looking great at present. However | Condors rugby | investorshub | 02/23/2021 2:47:53 PM |
With a price target of 49 and extremely | Condors rugby | investorshub | 02/12/2021 4:46:27 PM |
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging...
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...